Provided by Tiger Trade Technology Pte. Ltd.

Natera

410.35
+1.880.46%
Post-market: 410.350.00000.00%19:54 EDT
Volume:2.16M
Turnover:878.67M
Market Cap:58.77B
PE:-298.89
High:413.36
Open:409.40
Low:401.00
Close:408.47
52wk High:427.47
52wk Low:157.43
Shares:143.22M
Float Shares:139.00M
Volume Ratio:1.19
T/O Rate:1.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3729
EPS(LYR):-1.5269
ROE:-12.54%
ROA:-8.08%
PB:32.26
PE(LYR):-268.76

Loading ...

Natera Clinical Milestones Raise Questions On Growth Versus Valuation Risk

Simply Wall St.
·
May 27

Natera Upgrades Prenatal Test to Improve low Fetal Fraction Accuracy

MT Newswires Live
·
May 26

Natera launches enhanced Panorama NIPT backed by 3,323-patient clinical validation study

Reuters
·
May 26

Natera presents 35 oncology studies at ASCO annual meeting

Reuters
·
May 22

Natera presents ASCO data showing Signatera MRD positivity predicts higher recurrence risk

Reuters
·
May 22

Natera Expands Operations in Austin

MT Newswires Live
·
May 21

Natera announces expansion into Austin, creating largest sequencing factory

TIPRANKS
·
May 21

Natera Inc - Expects to Create up to 400 New Jobs Through Expansion

THOMSON REUTERS
·
May 21

Natera Inc - to Open New Sequencing Facility and Additional Space in North Austin

THOMSON REUTERS
·
May 21

Natera expands Austin operations, plans up to 400 new jobs

Reuters
·
May 21

Natera Expands Enrollment in Fetal Genetic Testing Study

MT Newswires Live
·
May 20

Natera announces Expand trial enrolled over 2,000 patients

TIPRANKS
·
May 20

Natera says EXPAND trial of Fetal Focus single-gene NIPT tops 2,000 enrollees

Reuters
·
May 20

Expand Trial of Natera’s Fetal Focus™ Single-Gene Nipt Surpasses >2,000 Patients Enrolled

THOMSON REUTERS
·
May 20

FDA Nod For Signatera MRD Blood Test Might Change The Case For Investing In Natera (NTRA)

Simply Wall St.
·
May 20

Judge sanctions law firm Quinn Emanuel, citing ethical lapses

Reuters
·
May 20

Natera co-founder, director Sheena Jonathan sells USD 694,798 in shares

Reuters
·
May 16

Natera's Signatera CDx Approved by FDA as Companion Diagnostic in Muscle-Invasive Bladder Cancer

MT Newswires Live
·
May 16

FDA Approves Atezolizumab For Adjuvant Treatment Of Muscle Invasive Bladder Cancer In Some Patients

Reuters
·
May 16

FDA approves Roche’s Tecentriq for ctDNA-guided adjuvant muscle-invasive bladder cancer treatment

Reuters
·
May 16